Form 4: Artiva Biotherapeutics SVP, Research and Development, Heather Raymon, Reports Acquisition of 10,000 Shares

Heather Raymon, SVP of Research and Development at Artiva Biotherapeutics, reports the acquisition of 10,000 shares of common stock through a restricted stock unit award.

Summary

• On September 12, 2024, Heather Raymon, SVP of Research and Development at Artiva Biotherapeutics, acquired 10,000 shares of common stock.
• The acquisition was a result of a restricted stock unit (RSU) award granted under the Issuer's 2024 Equity Incentive Plan.
• The price per share for the acquisition was $0.
• Following the transaction, Raymon directly owns 10,000 shares of Artiva Biotherapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating an executive's stock acquisition, which can be interpreted as a slightly positive signal of confidence, but it's not inherently a strong indicator.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders, like Heather Raymon, transact in their company's stock. It provides transparency to the market regarding insider activity.

Key Dates